In vitro antimicrobial inhibition profiles of Mycoplasma bovis isolates recovered from various regions of the United States from 2002 to 2003.
about
Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial SusceptibilityMycoplasma bovis infections in cattle.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central EuropeOverall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovisAlterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal.Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China.Mycoplasma bovis pneumonia in cattle.In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species.The effect of antimicrobial treatment and preventive strategies on bovine respiratory disease and genetic relatedness and antimicrobial resistance of Mycoplasma bovis isolates in a western Canadian feedlotMycoplasma bovis real-time polymerase chain reaction assay validation and diagnostic performance.Mycoplasma bovis isolates from dairy calves in Japan have less susceptibility than a reference strain to all approved macrolides associated with a point mutation (G748A) combined with multiple species-specific nucleotide alterations in 23S rRNA.Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model.In vitro antimicrobial susceptibility of Mycoplasma bovis clinical isolates recovered from bison (Bison bison).Treatment of naturally occurring bovine respiratory disease in juvenile calves with a single administration of a florfenicol plus flunixin meglumine formulation.Development of a physiologically based pharmacokinetic model to predict tulathromycin distribution in goats.Antimicrobial susceptibilities of Mycoplasma isolated from bovine mastitis in Japan.In vitro antimicrobial inhibition of Mycoplasma bovis isolates submitted to the Pennsylvania Animal Diagnostic Laboratory using flow cytometry and a broth microdilution method.Tulathromycin assay validation and tissue residues after single and multiple subcutaneous injections in domestic goats (Capra aegagrus hircus)Pharmacokinetics of tulathromycin after single and multiple subcutaneous injections in domestic goats (Capra aegagrus hircus)The safety of tulathromycin administration in goats
P2860
Q26747448-069A9C37-4305-46D9-A911-D72F243987A3Q34199444-73CE2B49-15C1-4E80-B606-115F83C4A2C0Q34410139-3C030A91-44A9-4E93-B75F-C6E4C5173AA6Q35087670-1E896A91-8EFF-4901-BB2D-D93B3E58668FQ35105951-1303CBAD-FCB6-4E3C-ADBB-14F68728E133Q36575147-26BC6C46-C10C-4ECF-AAA6-64AF4B0F9599Q36669885-E093B0AE-2A33-482F-81DB-68FA2A97B0E2Q37064551-142E7464-E5EA-405F-82BE-46C8ECDB9CF2Q37268241-13656783-C7F1-44BC-87ED-DDB701E0AED8Q37317944-C59F885B-322B-429B-B4B6-2794C0FC77FAQ37810710-D99A29A5-5086-4D5F-B510-16BCA3F0AFEBQ40212926-A86729E1-DE0C-4C87-819F-77DF1A4C3C21Q40329438-4BAC1398-C1CC-4A74-A383-9D4EE203E533Q40800942-55141D45-9ECF-43D3-A347-9F704909F7B6Q42225276-8B82B873-374B-4430-B687-71FEA7F5CA97Q43606297-1B492977-8084-48F2-91A1-B9CBD41D7D6BQ43973621-D86A1EBF-1F39-44AD-BF8A-FFE1371D6635Q53407054-DE1A9D38-BBFD-41B2-B50A-7F328C7DDC98Q57432140-5C928B1E-4185-402A-81BA-14AC0B7C47D0Q57434856-2A58F6F3-EF30-4230-8336-D2811322C900Q57981828-A595A45B-7B78-4D96-A591-9535CAC64C98
P2860
In vitro antimicrobial inhibition profiles of Mycoplasma bovis isolates recovered from various regions of the United States from 2002 to 2003.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@en
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@nl
type
label
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@en
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@nl
prefLabel
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@en
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@nl
P2093
P2860
P1476
In vitro antimicrobial inhibit ...... ited States from 2002 to 2003.
@en
P2093
Joann M Kinyon
Lorraine J Hoffman
Michael Apley
Nathan D Funk
Ricardo F Rosenbusch
Sean Smith
P2860
P304
P356
10.1177/104063870501700505
P577
2005-09-01T00:00:00Z